Novo Nordisk said Monday that its type-2 diabetes treatment Xultophy has shown superior efficacy in reducing Hemoglobin A1c (HbA1c) level, weight change, and the hypoglycemia events with a lower dose in phase 3 clinical trials.
Kangbuk Samsung Hospital Professor Lee Eun-jeong and Seoul National University Hospital Professor Cho young-min presented their study results at a recent symposium to celebrate the new drug launch.
People with type 2 diabetes whose blood sugar level does not respond with insulin glargine U100 and metformin were treated with Novo Nordisk’s Xultophy and showed non-inferiority in the glycated hemoglobin reduction effect in HbA1c changes compared to those who took insulin glargine U100 and insulin aspart combination therapy, they said.
People treated with Xultophy also experienced weight loss of 0.9 kilograms compared to those who gain 2.6 kg treated with the insulin glargine U100 and insulin aspart, showing excellent efficacy in controlling weight gain.
Xultophy also decreased the risk of developing hypoglycemia by 89 percent compared to those treated with insulin glargine U100 and insulin aspart.
The company conducted the study for 26 weeks with 506 type 2 diabetes patients whose blood sugar level does not respond with insulin glargine U100 and metformin.
“We held the workshop to help raise medical experts’ interests in Xultophy, which has an upgraded control of blood sugar level and weight gain over the existing insulin and oral hypoglycemic drugs or insulin glargine,” Novo Nordisk CEO Rana Asfar Zafar said.
Zafar added that the company hopes Korean type 2 diabetics who have difficulty managing blood sugar level, weight control, and hypoglycemia to enjoy an improved quality of life through various treatment options.
Xultophy is combined with a fixed ratio of Tresiba (ingredient: insulin degludec) and (ingredient: liraglutide), and it controls blood sugar levels in adults with type 2 diabetes.
Patients can inject Xultophy, which includes glucagon-like peptide 1 (GLP-1) receptor agonist and basal insulin, anytime in a day once regardless of having a meal.